ChromaDex Corporation Reports First Quarter 2024 Financial Results Total net sales of $22.2 million, gross margin of 60.7%, a net loss of $0.5 million and a positive Adjusted EBITDA of $0.7 million for the three months ended March 31, 2024. Reiterated full year outlook including net sales growth of at least 16%. LOS ANGELES, CA - May 8, 2024 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the first quarter of 2024. First Quarter 2024 Financial and Recent Operational Highlights • Total ...

Notes to the Unaudited Condensed Consolidated Financial Statements Disaggregation of Revenue The Company disaggregates its revenue from contracts with customers by type of goods or services for each of its segments, as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. Disaggregated revenues are as follows: | --- | --- | --- | --- | --- | --- | --- | |------------------------------------------------------------- ...

Watson's sales were lower due to a challenging comparison in the prior year, which benefited from a catch-up in shipments from earlier quarters as the business gradually recovered post-COVID. Other B2B sales were also down modestly due to the timing of partner sales, which are less predictable. And then as a follow-up with regard to a couple of your partners. Any comments on Watson's and perhaps talk about some of the sell-through trends that you're seeing, and also on Nestle? Perhaps talk about some of the ...

| --- | |-------------------------------------| | | | Net income (loss), as reported | | Adjustments | | Interest (income) expense | | Depreciation | | Amortization of intangibles | | Amortization of right of use assets | | Share-based compensation | | | | Severance and restructuring | 2021 – 2023 Net Sales Summary 2. Q4 2023 Net Sales Q4 2023 Net Sales ($ in millions) Other Ingredients $17.6 YoY % (vs Q4 2022) +20% | --- | --- | |-------|-------| | | (14)% | | | | | | | | | (30)% | | | (19)% | +16% Total + ...

FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 For the transition period from to . Delaware 26-2940963 (State or other jurisdiction of incorporation) (I.R.S. Employer Identification No.) or Commission file number 001-37752 10900 Wilshire Blvd. Suite 600, Los Angeles, CA 90024 (Address of Principal Executive Offices and Zip Code) This Annual Report on Form 10-K (Form 10-K) contains "forward-looking statements" withi ...

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, March 6, 2024 at 4:30 p.m. ET to discuss its financial results for the fourth quarter, which ended December 31, 2023. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call. Investor Conference Call: ChromaDex managemen ...

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 12, 2024, at 11:00 AM PST. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend this live event. The presentation will fe ...

LOS ANGELES--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber, will be participating in the Lytham Partners 2024 Investor Select Conference. Mr. Fried and Mrs. Gerber will participate in virtual one-on-one meetings throughout the event on Thursday, February 1, 2024. To arrange a meeting with the ChromaDex mana ...

MirageC/Moment via Getty Images In the volatile arena of healthcare investments, investors are constantly seeking opportunities that not only offer lucrative returns but also align with the developing trends in the sector. One such promising industry that has been gaining traction is the nutraceuticals and supplement industry. As the global population becomes increasingly health-conscious, there is a surge in demand for products that promote well-being. Nutraceuticals and supplements, which include vita ...

(3) | --- | --- | |--------------------|-------| | | | | ChromaDex | | | | | | | | | | | | Third Quarter 2023 | | Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | November 8, 2023 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amende ...